<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>POINT</h3></div><p><span class="main">"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA". The New England Journal of Medicine. Published May 16, 2018. </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/POINT>Wiki Journal Post</a>
                                        <a href=https://www.nejm.org/doi/full/10.1056/NEJMoa1800410>Full Journal Article</a>
                                        </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Does the combination of clopidogrel and aspirin improve outcomes compared to aspirin alone in patients with minor ischemic stroke or high-risk TIA?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with minor ischemic stroke or high-risk TIA, the combination of clopidogrel and aspirin reduced the risk of major ischemic events but increased the risk of major hemorrhage at 90 days compared with aspirin alone.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Combination therapy of clopidogrel and aspirin may decrease the recurrence of stroke after minor ischemic stroke or TIA. The POINT trial extended the findings from the CHANCE trial (in a Chinese population) by assessing this combination therapy in a diverse international population.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">At the time of the POINT trial publication, guidelines did not routinely recommend combined clopidogrel and aspirin for the treatment of stroke.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial
- N=4,881 patients
- Clopidogrel + aspirin vs. aspirin alone
- Enrolment: May 28, 2010, to December 19, 2017
- Follow-up: 90 days
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- At least 18 years of age
- Had a minor ischemic stroke (NIHSS score ≤3) or high-risk TIA (ABCD2 score ≥4) within 12 hours prior
- Underwent imaging to rule out intracranial hemorrhage or other mimics
- Major exclusions: Candidates for thrombolysis/thrombectomy, contraindication to aspirin or clopidogrel, anticipated need for NSAID use beyond 7 days
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Clopidogrel (600 mg on day 1, followed by 75 mg per day) + aspirin (50 to 325 mg per day) vs. aspirin alone (same dose range)
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Primary efficacy outcome: Composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes at 90 days
- Major hemorrhage was the primary safety outcome
 </span></p><h2><span class="labels">Criticisms</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Lower-than-expected overall event rates, particularly in TIA patients with low ABCD2 scores
- The study population did not represent moderate-to-severe stroke, cardioembolic stroke, or candidates for thrombolysis/thrombectomy
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- National Institute of Neurological Disorders and Stroke
- Sanofi provided clopidogrel and placebo for 75% of patients
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">POINT ClinicalTrials.gov number, NCT00991029 </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>